Form 4: Moderna Legal Chief's RSU Vesting and Tax-Related Sale

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc. (MRNA), reported transactions on August 29, 2025.
• Acquired 232 shares of common stock through the conversion of restricted stock units (RSUs).
• Disposed of 113 shares of common stock at a price of $24.47 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Klinger directly beneficially owns 28,170 shares of Moderna common stock.
• The RSUs convert into common stock on a one-for-one basis.
• The RSU award's vesting schedule began with 25% vesting on March 1, 2023, with the remaining shares vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine, reflecting executive compensation and tax management. The executive retains a significant stake, which is positive for alignment, but the sale for taxes is a minor negative in terms of direct ownership reduction.

Positives

• The vesting of Restricted Stock Units indicates the achievement of performance or tenure milestones by a key executive.
• The executive continues to hold a significant number of shares (28,170), aligning their interests with shareholders.

Negatives

• A portion of the vested shares (113 shares) was sold to cover tax obligations, which is a common practice but represents a reduction in direct ownership.

Future Outlook

The remaining restricted stock units will continue to vest in twelve equal quarterly installments following the initial March 1, 2023 vesting date.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies where executives receive equity awards.

Comparison to Industry Standards

• The practice of executives receiving Restricted Stock Units (RSUs) as part of their compensation package and subsequently selling a portion of vested shares to cover tax liabilities is standard across the pharmaceutical and biotechnology industry, similar to practices at companies like Pfizer, BioNTech, or Johnson & Johnson.
• The one-for-one conversion of RSUs to common stock is also a typical structure for such awards.

Related Party Transactions

• The reported transactions involve the vesting and disposition of shares by a company officer, which is an internal, compensation-related transaction.

Stakeholder Impact

• Shareholders: Minor impact, as it's a routine compensation event. The executive's continued significant ownership aligns interests.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Continued vesting of remaining restricted stock units in equal quarterly installments.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a tax-related sale by a key executive. Such transactions are standard compensation events and do not typically indicate a change in the company's fundamental outlook or performance. The executive retains a substantial equity stake, which is a positive for management-shareholder alignment. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further operational or financial news.

Keywords

Moderna, MRNA, Shannon Thyme Klinger, Chief Legal Officer, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding